NCT02298959 - Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 8, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Colorectal CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Ovarian CarcinomaMetastatic Renal Cell CarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent MelanomaRecurrent Renal Cell CarcinomaRefractory MelanomaRefractory Renal Cell CarcinomaSarcomaStage IV Colorectal Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8

Interventions

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Elastography

Undergo MRI

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Ziv-Aflibercept

Given IV

Trial Locations (9)

20892

National Cancer Institute Developmental Therapeutics Clinic, Bethesda

National Institutes of Health Clinical Center, Bethesda

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center - McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH